Valneva (VALN) Competitors $5.88 -0.19 (-3.13%) As of 06/17/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock VALN vs. SRPT, RXRX, APGE, IDYA, INDV, CGON, BLTE, GLPG, HRMY, and IRONShould you be buying Valneva stock or one of its competitors? The main competitors of Valneva include Sarepta Therapeutics (SRPT), Recursion Pharmaceuticals (RXRX), Apogee Therapeutics (APGE), IDEAYA Biosciences (IDYA), Indivior (INDV), CG Oncology (CGON), Belite Bio (BLTE), Galapagos (GLPG), Harmony Biosciences (HRMY), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. Valneva vs. Its Competitors Sarepta Therapeutics Recursion Pharmaceuticals Apogee Therapeutics IDEAYA Biosciences Indivior CG Oncology Belite Bio Galapagos Harmony Biosciences Disc Medicine Sarepta Therapeutics (NASDAQ:SRPT) and Valneva (NASDAQ:VALN) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk. Does the MarketBeat Community prefer SRPT or VALN? Sarepta Therapeutics received 1446 more outperform votes than Valneva when rated by MarketBeat users. Likewise, 74.74% of users gave Sarepta Therapeutics an outperform vote while only 66.67% of users gave Valneva an outperform vote. CompanyUnderperformOutperformSarepta TherapeuticsOutperform Votes148874.74% Underperform Votes50325.26% ValnevaOutperform Votes4266.67% Underperform Votes2133.33% Which has more risk & volatility, SRPT or VALN? Sarepta Therapeutics has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500. Comparatively, Valneva has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500. Is SRPT or VALN more profitable? Sarepta Therapeutics has a net margin of -11.12% compared to Valneva's net margin of -43.08%. Sarepta Therapeutics' return on equity of -14.88% beat Valneva's return on equity.Company Net Margins Return on Equity Return on Assets Sarepta Therapeutics-11.12% -14.88% -5.12% Valneva -43.08%-43.05%-16.23% Do analysts rate SRPT or VALN? Sarepta Therapeutics currently has a consensus target price of $74.13, indicating a potential upside of 243.83%. Valneva has a consensus target price of $15.50, indicating a potential upside of 163.61%. Given Sarepta Therapeutics' higher possible upside, research analysts clearly believe Sarepta Therapeutics is more favorable than Valneva.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sarepta Therapeutics 1 Sell rating(s) 10 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.54Valneva 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, SRPT or VALN? Sarepta Therapeutics has higher revenue and earnings than Valneva. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSarepta Therapeutics$1.90B1.11$235.24M-$2.69-8.01Valneva$183.52M2.73-$13.25M-$1.19-4.94 Do institutionals & insiders believe in SRPT or VALN? 86.7% of Sarepta Therapeutics shares are held by institutional investors. Comparatively, 11.4% of Valneva shares are held by institutional investors. 7.7% of Sarepta Therapeutics shares are held by company insiders. Comparatively, 14.9% of Valneva shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor SRPT or VALN? In the previous week, Sarepta Therapeutics had 83 more articles in the media than Valneva. MarketBeat recorded 87 mentions for Sarepta Therapeutics and 4 mentions for Valneva. Valneva's average media sentiment score of 0.70 beat Sarepta Therapeutics' score of -0.35 indicating that Valneva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 7 Very Positive mention(s) 15 Positive mention(s) 23 Neutral mention(s) 21 Negative mention(s) 6 Very Negative mention(s) Neutral Valneva 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummarySarepta Therapeutics beats Valneva on 12 of the 19 factors compared between the two stocks. Get Valneva News Delivered to You Automatically Sign up to receive the latest news and ratings for VALN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VALN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VALN vs. The Competition Export to ExcelMetricValnevaMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$510.26M$10.12B$5.33B$8.57BDividend YieldN/A2.08%5.32%4.20%P/E Ratio-4.9418.0925.9419.01Price / Sales2.7328.95424.50111.98Price / Cash61.3722.6335.6355.74Price / Book2.443.607.825.05Net Income-$13.25M$232.68M$3.15B$249.31M7 Day Performance-4.87%-3.46%-2.62%-1.87%1 Month Performance-6.89%-1.64%4.42%2.24%1 Year Performance-17.18%-15.22%35.79%15.05% Valneva Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VALNValneva2.5109 of 5 stars$5.88-3.1%$15.50+163.6%-17.0%$510.26M$183.52M-4.94700Gap DownSRPTSarepta Therapeutics4.5668 of 5 stars$20.94-42.1%$99.35+374.4%-81.5%$2.06B$2.23B16.75840Trending NewsAnalyst ForecastOptions VolumeHigh Trading VolumeRXRXRecursion Pharmaceuticals1.9094 of 5 stars$5.00+1.6%$7.00+40.0%-48.3%$2.03B$59.82M-3.27400Analyst ForecastAPGEApogee Therapeutics2.4271 of 5 stars$42.61-4.2%$94.60+122.0%+6.8%$1.96BN/A-17.6191Positive NewsIDYAIDEAYA Biosciences3.7793 of 5 stars$22.39+0.9%$54.27+142.4%-41.6%$1.96B$7M-6.7880INDVIndivior2.7307 of 5 stars$14.18+2.1%$15.00+5.8%-15.7%$1.96B$1.17B-40.511,164Positive NewsCGONCG Oncology2.4732 of 5 stars$25.46-1.5%$58.22+128.7%-22.2%$1.94B$662K-16.8661Positive NewsAnalyst ForecastBLTEBelite Bio2.6529 of 5 stars$59.99+0.7%$96.67+61.1%+18.0%$1.91BN/A-54.0410Short Interest ↑GLPGGalapagos0.2173 of 5 stars$28.80+0.1%$25.33-12.0%+8.5%$1.90B$288.19M0.001,310HRMYHarmony Biosciences4.7827 of 5 stars$32.90-0.2%$53.00+61.1%+10.6%$1.89B$744.85M15.59200Positive NewsShort Interest ↑IRONDisc Medicine2.204 of 5 stars$52.02-3.1%$96.70+85.9%+11.6%$1.80BN/A-13.0730Analyst ForecastAnalyst Revision Related Companies and Tools Related Companies SRPT Alternatives RXRX Alternatives APGE Alternatives IDYA Alternatives INDV Alternatives CGON Alternatives BLTE Alternatives GLPG Alternatives HRMY Alternatives IRON Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VALN) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored72 Hours Until Musk’s $34 Trillion AI Network BeginsIn just 72 hours, Elon Musk is expected to flip the switch on Tesla’s autonomous network in Austin, Texas. ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | SponsoredPresident Trump Could Soon Unlock Trillions in New WealthIf you think America is broke, think again. These "reserve accounts" are worth trillions... And according t...InvestorPlace | SponsoredSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Valneva SE Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Valneva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.